Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-11-08
2010-06-22
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C436S086000, C514S015800, C514S017400, C514S018700, C530S327000, C530S329000, C530S330000
Reexamination Certificate
active
07741288
ABSTRACT:
The present invention relates to methods for identifying novel PP1-interacting polypeptides and proteins, compounds which are able to inhibit the binding of PP1c to certain factors naturally interacting with it, especially proteins of the Bcl-2 family (such as BCl-xLand Bcl-w), and pharmaceutical compositions comprising the same.
REFERENCES:
patent: 6884600 (2005-04-01), Cohen et al.
patent: 7253269 (2007-08-01), Ohta et al.
patent: 2003/0130484 (2003-07-01), Gordon et al.
patent: 2003/0176671 (2003-09-01), Reed et al.
patent: WO 01/12807 (2001-02-01), None
Reed, “Bcl-2 family proteins,” Oncogene, 1998, 17, 3225-36.
Bollen, “Combinatorial control of protein phosphatase-1,” TIBS, 2001, 26, 426-31.
Ammosova et al., “Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein,” J. Biol. Chem., 2005, 280, 36364-71.
Richter et al., “Inhibitors of HIV-1 Tat-mediated transactivation,” Curr. Med. Chem., 2006, 13, 1305-15, abstract only.
Ginalski et al. “Practical lessons from protein structure prediction.” Nuc. Ac. Res., 2005, 33, 1874-1891.
Rudinger “Characteristic of the amino acids as components of a peptide hormone sequence.” (Peptide Hormones (Ed. J.A. Parson). University Park Press. Baltimore, 1976, pp. 1-7.
Pitt et al. “Single amino acid substitution mutants ofKlebsiella pneumoniaesingma54 defective in transcription” Nuc. Ac. Res., 2000, 28, 4419-4427.
Bradley et al. “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Subsitutions in Each Repeat” J. Mol. Biol., 2002, 324, 373-386.
Flanagan et al. “Truncated staphyloccal nuclease is compact but disordered” Proc. Natl. Acad. Sci. USA, 1992, 89, 748-752.
Schnog et al. “Sickle cell disease; a general overview” J. Med., 2004, 62, 364-374.
Sawai et al. “Impact of single-residue mutations on the structure and function of ovispirin
ovispirin antimicrobial peptides” Prot. Engin., 2002, 15, 225-232.
Chene, “Drugs targeting protein-protein interactions,” Chem. Med. Chem., 2006, 4, 400-11, abstract only.
CAPLUS Accession No. 1995:55584.
Oh et al. “Structure-activity relationship study: short antimicrobial peptides,” J. Pept. Res., 1999, 53, 41-6.
Lowe et al. “Structure-Function Relationships for Inhibitors of beta-Amyloid Toxicity Containing the Recognition Sequence KLVFF,” Biochemistry., 2001, 40, 7882-9.
Valerio et al. Multiple peptide synthesis on acid-labile handle derivatized polyethylene supports. International Journal of Peptide & Protein Research. 1994, vol. 44, pp. 158-165.
Veronica Ayllon, et al., “Protein phosphatase 1α is a Ras-activated Bad phosphatase that regulates interleukin-2 deprivation-induced apoptosis”, The EMBO Journal, vol. 19, No. 10, 2000, pp. 2237-2246.
Patricia T. W. Cohen, “Protein phosphatase 1-targeted in many directions”, Journal of Cell Science, vol. 115, No. 2, 2002, pp. 241-256.
Marie-Pierre Egloff, et al., “Structural basis for the recognition of regulatory subunits by the catalytic subunit protein phosphatase 1”, The EMBO Journal vol. 16, No. 8, 1997, pp. 1876-1887.
Ayllon et al , J. of Immunology, 2001, vol. 166, No. 12, pp. 7345-7342.
Fernandez et al, Biochemistry 1994, vol. 33, No. 37, pp. 11073-11078.
Fukuda et al, Cancer Research 2000, vol. 60, pp. 450-456.
Ayllon et al, Eur. J. Immunol. 2002, vol. 32, No. 7, pp. 1847-1855.
Cayla Xavier
Garcia Alphonse
Rebollo Angelita
Institut National de la Recherche Agronomique (INRA)
Institut National de la Sante et de la Recherche Medicale
Institut Pasteur
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
Russel Jeffrey E
LandOfFree
Methods of screening of PP1-interacting polypeptides or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of screening of PP1-interacting polypeptides or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of screening of PP1-interacting polypeptides or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242390